Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Algeria

Algeria

In Algeria, the revenue in the market Other Vaccines market is estimated to reach US$46.02m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 9.51%, leading to a market volume of US$72.47m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$24,730.00m in 2024.
Algeria is experiencing a growing demand for other vaccines as the government prioritizes public health initiatives.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Algeria has seen significant growth in recent years.

Customer preferences: Algerian customers have shown a growing interest in preventative healthcare measures, including vaccinations. In particular, there has been an increased demand for vaccines that protect against infectious diseases such as meningitis and yellow fever.

Trends in the market: One of the key trends in the Other Vaccines market in Algeria is the increasing availability of vaccines in both urban and rural areas. The government has made efforts to improve healthcare infrastructure and increase access to vaccines, which has contributed to the growth of the market. Additionally, there has been a rise in public awareness campaigns promoting the importance of vaccination, which has further boosted demand.

Local special circumstances: Algeria has a relatively young population, with a large proportion of children and young adults. This demographic trend has contributed to the growth of the Other Vaccines market, as parents seek to protect their children from preventable diseases. Additionally, Algeria is a popular destination for tourists, which has increased the demand for vaccines that protect against infectious diseases such as yellow fever.

Underlying macroeconomic factors: Algeria is a middle-income country with a growing economy. This has allowed the government to invest in healthcare infrastructure and promote preventative healthcare measures such as vaccination. Additionally, Algeria has a relatively stable political environment, which has helped to attract foreign investment and contribute to economic growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.